Repurposing Anticancer Drugs for the Management of COVID-19


Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion, thus regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are limited, with an undefined or modest efficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use approved drugs outside the scope of their original indication and accelerate the discovery of new therapeutic options. With the emergence of COVID-19, drug repurposing has been largely applied for early clinical testing. In this Review, we discuss some repurposed anticancer drugs for the treatment of COVID-19 and under investigation in clinical trials or proposed for the clinical testing.

Read full text: El Bairi K, Trapani D, Petrillo A, Le Page C, Zbakh H, Daniele B, Belbaraka R, Curigliano G, Afqir S. Repurposing Anticancer Drugs for the Management of COVID-19. Eur J Cancer. 2020 Sep 22. doi: 10.1016/j.ejca.2020.09.014. Epub ahead of print. PMCID: PMC7508523.

Keywords: COVID-19, SARS-CoV-2, Anticancer drugs, Drug repurposing, #Pharmaceuticals, #Pharma.

The International Natural Product Sciences Taskforce (INPST) maintains up-to-date lists with conferencesgrants and funding opportunitiesjobs and open positions, and journal special issues with relevance for the area of phytochemistry and food chemistry, pharmacology, biotechnology, medicine and pharmacognosy research, and natural product science.

Join for free INPST as a member

INPST social media channels